BMS/Pfizer's Eliquis better than Lovenox, but comparison with Pradaxa and Xarelto not clear, says NICE
This article was originally published in Scrip
NICE, the health technology assessment body for England and Wales, has fast tracked Bristol-Myers Squibb's oral direct Factor Xa inhibitor, Eliquis (apixaban), through its appraisal process and has published final draft guidance recommending it for preventing blood clots after hip and knee surgery. The institute says it is both cheaper and more clinically effective than Sanofi's Lovenox, (enoxaparin). However, the jury is still out on how it compares to Boehringer Ingelheim's Pradaxa (dabigatran) and Bayer's Xarelto (rivaroxaban), partly because of the way in which the comparison was conducted.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.